Kinase inhibitor: AKT; Autophagy modulator. Inhibits SARS-CoV-2 in cells. Gassen et al. bioRxiv, Apr 15 2020, https://doi.org/10.1101/2020.04.15.997254.
- Datasheet: view or download
- Applications:In clinical trials for other indication(s)
Biochemicals & reagents
1) Hirai et al. (2010), MK-2206, an Allosteric Akt inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular targeted Drugs In vitro and In vivo; Mol.Cancer Ther. 9 1956 2) Lai et al. (2012), A novel PKB/Akt inhibitor, MK-2206, effectively inhibits insulin-stimulated glucose metabolism and protein synthesis in isolated rat skeletal muscle; Biochem.J. 447 137 3) Jiao et al. (2013), MK-2206 induces cell cycle arrest and apoptosis in HepG2 cells and sensitizes TRAIL-mediated cell death; Mol.Cell Biochem. 382 217
MK-2206 is a potent and selective allosteric inhibitor of Akt (IC50’s: Akt1 = 5 nM, Akt2 = 12 nM, Akt3 = 65 nM) that enhances the in vitro and in vivo antitumor efficacy of several standard chemotherapeutic agents (1). This compound was able to decrease insulin-stimulated glucose uptake, glycogen synthesis and glycogen synthase activity in rat muscle (2). It has also been shown that MK-2206 induced G1-phase cycle arrest and sensitized HepG2 hepatocellular carcinoma cells to TRAIL-induced apoptosis (3).